



TEN 1642



Please Direct All Correspondence to Customer Number **30,313**

TRANSMITTAL LETTER

INFORMATION DISCLOSURE STATEMENT

Applicant	:	Goddard, et al.
App. No	:	10/063,518
Filed	:	May 1, 2002
For	:	SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME
Examiner	:	Larry Ronald Helms
Art Unit	:	1642

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 17, 2005

(Date)

Daniel Hart, Reg. No. 40,637

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing references for consideration:
 - (X) Listing four (4) references.
 - (X) Enclosing four (4) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Daniel Hart
Registration No. 40,637
Attorney of Record
Customer No. 30,313
(619) 235-8550



Packet No.: GNE.3230R1C10



Customer No. 30,313

INFORMATION DISCLOSURE STATEMENT

Applicant : Goddard, et al.
App. No : 10/063,518
Filed : May 1, 2002
For : SECRETED AND TRANSMEMBRANE
POLYPEPTIDES AND NUCLEIC
ACIDS ENCODING THE SAME
Examiner : Larry Ronald Helms
Art Unit : 1642

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

November 17, 2005

(Date)

Daniel Hart, Reg. No. 40,637

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing four (4) references to be considered by the Examiner. Also enclosed are four (4) foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed within three months after the filing of an RCE and no fee is required.

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: Nov. 17, 2005

By: Daniel Hart

Daniel Hart
Registration No. 40,637
Attorney of Record
Customer No. 30,313
(619) 235-8550



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Multiple sheets used when necessary)

SHEET 1 OF 1

Application No.	10/063,518
Filing Date	May 1, 2002
First Named Inventor	Goddard, et al.
Art Unit	1642
Examiner	Larry Ronald Helms
Attorney Docket No.	GNE.3230R1C10

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ¹

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1	LABAER, Joshua. 2003. Letter to the editor: Mining the literature and large datasets. <i>Nature Biotechnology</i> , 21(9):976-977.	
	2	LIAN, et al. 2001. Genomic and proteomic analysis of the myeloid differentiation program. <i>Blood</i> , 98(3):513-524.	
	3	LICHTINGHAGEN, et al. 2002. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. <i>European Urology</i> , 42:398-406.	
	4	YOUSEF, et al. 2003. Parallel overexpression of seven kallikrein genes in ovarian cancer. <i>Cancer Research</i> , 63:2223-2227.	

2074523:dmn
111605

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

¹ - Place a check mark in this area when an English language Translation is attached.